BioSpace News Archive

AstraZeneca’s Farxiga (dapagliflozin) dramatically prolonged survival in patients with chronic kidney disease in a Phase III clinical trial.

When Bionano Genomics acquired Lineagen, Inc. in August, the genomic analysis company gained the final piece it needed to provide comprehensive structural variation detection for researchers and drug developers and a reimbursement pathway for clinicians who want to use its technology to replace cytogenetic tests to diagnose cancers and rare diseases.

Jayson Dallas, president and chief executive officer of Aimmune, said the agreement with Nestlé recognizes the value of Aimmune’s longtime commitment to advancing therapies for food allergies.

Shares of Akcea Therapeutics were up more than 58% in premarket trading after its majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24% of available stock for $18.50 per share.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.

On Sunday, U.S. Food and Drug Administration Commissioner Stephen Hahn told the Financial Times that he would potentially fast-track a COVID-19 vaccine before clinical trials are done if it was “appropriate.”

As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.

Research published in Lancet Oncology August 24th analyzed that risk by tumor subtype and patient demographics, looking at 1,044 patients from 60 medical centers throughout the UK.

Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that detailed results from the Phase 2 HELP Study of levosimendan in PH-HFpEF have been accepted for presentation as a Late-Breaking Clinical Trial at this year’s Heart Failure Society of America (HFSA) Annual Scientific Meeting